LIF As We Know It: From Basic Science to Clinical Trials
Roger Doxat-Pratt: roger.doxat-pratt@nottingham.ac.uk
We are living in very exciting times in the context of molecular oncology. A deeper understanding of the molecular mechanisms involved cancer is revealing novel therapeutic approaches to treat cancer. A new and exciting therapeutic target has emerged recently. LIF is a cytokine aberrantly expressed in cancer that acts as a pleiotropic oncogenic factor. It regulates cancer stem cells, the tumour microenvironment and specifically the immune system.
In this conference, we will learn about the most recent advances in the field of LIF from the basic science to clinical studies including the understanding of its biology, its implications in cancer and the development of anti-cancer agents.
The target audience for this conference is basic and translational scientists and clinicians, both senior and young investigators that want to have a broad and detailed overview of the most recent advances in the field of LIF.
